Nufarm (ASX:NUF)- CEO, Greg Hunt
CEO, Greg Hunt
Source: Nufarm
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • The US Food and Drug Administration (FDA) recognises Nufarm’s (NUF) Nuseed omega-3 canola oil as a new dietary ingredient
  • The company has created a plant-based source of omega-3 fatty acids as an alternative to fish oil, the most common source of omega-3
  • According to NUF, the oil will help reduce pressure on wild-fish stocks
  • CEO Greg Hunt said FDA approval is a huge milestone for the company
  • On market close for the day, Nufarm was up 3.21 per cent and is trading at $4.50 per share

The US Food and Drug Administration (FDA) has recognised Nufarm’s (NUF) Nuseed omega-3 canola oil as a new dietary ingredient.

The company has created a plant-based source of omega-3 fatty acids and is an alternative to fish oil, the most common source of omega-3.

Omega-3 have several health benefits, such as lowering blood pressure and raising.

Nuseed’s omega-3 canola helps fill the gap between how much long-chain omega-3 is needed to support human and animal nutrition and how little the ocean can sustainably provide.

CEO Greg Hunt said FDA approval is a huge milestone for the company.

“The FDA’s acknowledgment along with our recently completed human clinical trial, allows us to progress our plans to expand into the human nutrition market and meet a growing demand for plant-based omega-3 essential oil options,” Mr Hunt said.

“With FDA recognition of Nuseed’s conclusion that Nutriterra is a safe new dietary ingredient, we are well placed to secure commercial partnerships that will attract new consumers, enter into new segments and raise consumption of omega-3.”

Notably, a human trial was conducted with the omega-3 canola oil and showed participants absorbing the oil’s omega-3s.

On market close for the day, Nufarm was up 3.21 per cent and is trading at $4.50 per share.

NUF by the numbers
More From The Market Herald

" Creso Pharma (ASX:CPH) signs potential partnership with Gotro for Sierra pet products

Creso Pharma (ASX:CPH) signs a heads of agreement with leading pet care distributor, Gotro Global, to…
The Market Herald Video

" Botanix Pharmaceuticals (ASX:BOT) accelerates Sofpironium Bromide NDA filing

Botanix Pharmaceuticals (ASX:BOT) has accelerated the submission of a New Drug Approval (NDA) for its Sofpironium…
The Market Herald Video

" ResApp (ASX:RAP) extends Medgate licence agreement in line with expansion plans

ResApp Health (ASX:RAP) has agreed to a 12 month extension to its commercial licence agreement with…

" Alterity Therapeutics (ASX:ATH) doses first patient in MSA trial

Alterity Therapeutics (ASX:ATH) doses its first patient in a clinical trial for a rare Parkinsonian disorder.